drugset
drugset / Trial / NCT03463265

Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

NCT03463265 ↗

Phase 2 Completed 62 enrolled Aadi Bioscience, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma. nab-Sirolimus was administered as single agent or in combination therapies.

Timeline

Start
2018-08-01
Primary completion
2022-08-26
Completion
2022-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Subject Lomustine Small molecule 90 mg/m2 Oral
Subject Marizomib Small molecule 0.8 mg/m2 Intravenous
Subject Temozolomide Small molecule 50 mg/m2 Oral
Subject Temozolomide Small molecule 75 mg/m2 Oral
Subject Temozolomide Small molecule 150 mg/m2 Oral
Subject nab-sirolimus Unknown 60 mg/m2 Intravenous
Subject nab-sirolimus Unknown 100 mg/m2 Intravenous

Indications

glioblastoma